Preclinical studies confirmed that ralimetinib inhibits p38 kinase activity as well as the secretion of IL-6 [33], a pro-inflammatory cytokine and external key regulator of pEMT in HNSCC [8,35]. The gene discussed is PEMT; the disease is head and neck squamous cell carcinoma.